The New Dimension of Cancer: It is Not a Disease but a Deficiency of Vitamin B17

Authors

DOI:

https://doi.org/10.37591/rrjooh.v7i3.553

Abstract

Most commonly used an alternative drug in the treatment of tumor in the last 40 years is Amygdalin. Treatment based on the use of Vitamin B-17, proteolytic pancreatic enzymes, immunostimulants, vitamin and mineral supplements for cancer is a metabolic therapy which is nontoxic. National Cancer Institute is unsuccessful to prove that Laetrile is ineffective and toxic during their studies by clinical trials in 1981. Today, position on the "front lines" of alternative cancer therapy occupied by Amygdalin. Surgery, radiation and chemotherapy can only be administered for a limited time, but Amygdalin can be used indefinitely due to its nontoxicity nature. Combination of Amygdalin with other mineral and vitamin supplements showed effective therapy to treat cancer. Further studies should be conducted to make Laetrile available for the treatment of cancer patients to protect from toxic effects of chemotherapy.

 

Keywords: Amygdalin, Chemotherapy, Radiation, Surgery

 

Cite this Article

Giri Raja Sekhar, N. Sreeja. The New Dimension of Cancer: It is Not a Disease but a Deficiency of Vitamin B17. Research & Reviews: Journal of Oncology & Hematology. 2018; 7(3): 34–36p.

Downloads

Published

2019-01-23

Issue

Vol. 7 No. 3 (2018)

Section

Review Article

License

Declaration and Copyright Transfer Form

(to be completed by authors)

I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.

  • I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
  • I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
  • I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
  •  I/We also agree to the authorship of the article in the following order:

Author’s name                                    

 

1. ________________

2. ________________

3. ________________

4. ________________

 

We  Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal.